TICKERNERD
Menu
TWSTTWSTHealthcare · Biotechnology

TWST Stock Forecast: Twist Bioscience Corp. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$127
+0.29% on the day

The 13 Wall Street analysts covering Twist Bioscience Corp. hold a median 12-month price target of $115 — -9.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 65 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$8.4B
Ticker Nerd rank
65 / 100
Median analyst target
$115
Analysts covering
13
Revenue$118.4M+23.2% y/y
Operating income−$36.3M
Net income−$35.1M
Free cash flow−$8.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.2%
1M
+3.3%
YTD
+301.1%
1Y
+396.8%
From 52W high
−16.9%
From 52W low
+402.6%
$25
$153
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TWST stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Twist Bioscience Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
65 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
97
Quality
82
Revisions
65
Value
62
Accruals
60
Growth
52
Volatility
40
Issuance
29
Size
17

Momentum (97): The shares have been drifting up relative to others.

Issuance (29): The company has been issuing shares or taking on financing, diluting existing holders.

Size (17): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TWST stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TWST, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$50$100$150Oct 25Jan 26Apr 26Jul 26TWSTHigh $148Median $115Low $36

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
9 Buy3 Hold1 Sell
Low $36Median $115High $148

The green dot is the last close — the median target sits −9.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
9 Sept 2026BWS FinancialInitiatesSell$45
9 Sept 2026UBSInitiatesNeutral$144
5 Aug 2026Piper SandlerMaintainsOverweight$85 → $115
5 Aug 2026Piper SandlerMaintainsOverweight—
4 Aug 2026BairdMaintainsOutperform—
4 Aug 2026BairdMaintainsOutperform$113 → $115
14 July 2026Canaccord GenuityMaintainsBuy$90 → $120
14 July 2026Canaccord GenuityMaintainsBuy—
6 July 2026Evercore ISI GroupDowngradeIn-Line$66 → $102
6 July 2026Evercore ISI GroupDowngradeIn-Line—
29 June 2026GuggenheimMaintainsBuy$60 → $107
29 June 2026GuggenheimMaintainsBuy—
24 June 2026BarclaysMaintainsOverweight—
15 June 2026Canaccord GenuityInitiatesBuy—
15 June 2026TD CowenMaintainsBuy—
11 June 2026Piper SandlerInitiatesOverweight—
5 May 2026BairdMaintainsOutperform—
5 May 2026BarclaysMaintainsOverweight—
5 May 2026GuggenheimMaintainsBuy—
5 May 2026Leerink PartnersUpgradeOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TWST appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TWST vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Twist Bioscience Corp. returned +396.8% against +17.5% for the S&P 500, dividends included.

TWST vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500600Oct 25Jan 26Apr 26Jul 26TWSTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TWST analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Twist Bioscience Corp. (TWST) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−97.7×

Cheaper than 99% of US stocks

Price / sales
19.5×

Cheaper than 9% of US stocks

Price / book
17.9×

Cheaper than 5% of US stocks

EV / EBITDA
−68.7×

Cheaper than 95% of US stocks

Growth & margins
Revenue growth (YoY)
23.2%

Higher than 73% of US stocks

Earnings growth (YoY)
23.2%

Higher than 61% of US stocks

Gross margin
52.8%

Higher than 65% of US stocks

Operating margin
−30.6%

Higher than 20% of US stocks

Net margin
−31.7%

Higher than 13% of US stocks

Returns & dividend
Return on equity
−29.6%

Higher than 27% of US stocks

Return on assets
−13.1%

Higher than 24% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Twist Bioscience Corp. (TWST) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Twist Bioscience Corp. has a market value of $8.4B and an enterprise value of $7.9B.

  • Revenue in the twelve months to 30 June 2026: $431.8M. The latest quarter grew 23.2% year on year.

  • Net income over the same four quarters: −$136.7M, a −31.7% net margin.

  • Diluted earnings per share, trailing twelve months: $−2.22.

  • Free cash flow in the twelve months to 30 June 2026: −$93.2M.

  • Twist Bioscience Corp. spent $18K on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 62.7M.

  • Trailing P/E: −97.7×; forward P/E: −201.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Twist Bioscience Corp. employs 979 people — $441K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

TWST vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TWSTTwist Bioscience Corp.$8.4B
65
PCVXVaxcyte, Inc.$8.4B
53
IBRXImmunityBio, Inc.$8.3B
49
TGTXTG Therapeutics, Inc.$8.6B
68
CRNXCrinetics Pharmaceuticals, Inc.$8.7B
—
SYRESpyre Therapeutics, Inc.$7.8B
46
IONSIonis Pharmaceuticals, Inc.$9.0B
46

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Twist Bioscience Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TWST news & analysis

AI & Robotics in 2026: 16 Recent Developments for Investors

ETF Trends · 9 Sept 2026positive

An ETF Trends piece reports that August saw accelerating advances in AI and robotics, citing longer-running agents, faster and cheaper inference, AI systems engaging with laboratories and physical equipment, robots learning from fewer demonstrations, and new capital and infrastructure forming around commercial deployment.

Why it matters — AI capabilities reaching into laboratories and physical equipment could be relevant to TWST's synthetic biology and DNA-synthesis operations.

Twist Bioscience to Present at Baird 2026 Global Healthcare Conference

Business Wire · 9 Sept 2026neutral

Twist Bioscience announced that CEO and co-founder Emily M. Leproust and CFO Adam Laponis will participate in a fireside chat at the Baird 2026 Global Healthcare Conference on September 15, 2026, at 1:25 pm Eastern Time in New York City. The fireside chat will be webcast live.

Why it matters — TWST watchers may be interested in hearing management discuss the company's direction at a major healthcare investor conference.

Twist Biosciences: AI-Driven Rally Or Short Squeeze? I'm Neutral (For Now)

Seeking Alpha · 20 Aug 2026neutral

Seeking Alpha rates Twist Bioscience as Hold, noting its $9.5bn valuation appears disconnected from fundamentals and profitability remains elusive. The recent 200% stock surge is attributed to AI-related news, short-squeeze dynamics, and strong DSPS revenue growth rather than blowout earnings, while full-year 2026 guidance was raised to $456–$457m revenue with adjusted EBITDA breakeven targeted.

Why it matters — TWST watchers would care because the analysis questions whether the stock's recent AI-driven surge is justified by fundamentals versus market dynamics, and highlights persistent losses despite raised revenue guidance.

Twist Bioscience Stock Resilient Despite Scorpion Capital Short Report

Benzinga · 19 Aug 2026positive

Twist Bioscience shares rose after Anthropic named the company an independent evaluator in a new AI-driven protein design campaign. The stock remained resilient despite a short report from Scorpion Capital.

Why it matters — A TWST watcher would care because being selected by Anthropic as an independent evaluator in an AI protein design campaign is a notable endorsement that could expand the company's role in the growing AI-driven biotech space.

Alger Small Cap Growth Fund Q2 2026 Portfolio Review

Seeking Alpha · 14 Aug 2026positive

Alger Small Cap Growth Fund's Q2 2026 portfolio review reports that the Class A shares outperformed the Russell 2000 Growth Index during the quarter, with Twist Bioscience Corp. listed among the top contributors to fund performance.

Why it matters — A TWST watcher would care because the fund's review highlights Twist Bioscience as one of the strongest performers in its portfolio, signaling positive recognition from an institutional investor.

FAQ

Frequently asked questions about TWST stock

What is the TWST stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Twist Bioscience Corp. have a median 12-month price target of $115, with estimates ranging from $36 to $148. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TWST stock a buy right now?

Of the 13 analysts covering Twist Bioscience Corp., 9 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Twist Bioscience Corp. 65 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TWST?

As at 12 Sept 2026, Twist Bioscience Corp. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).

Will TWST stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies -9.6% from the last close, and Ticker Nerd's factor model ranks Twist Bioscience Corp. 65 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TWST stock forecast for 2030?

No analyst covering Twist Bioscience Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TWST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $36 to $148 over the next 12 months.

How has TWST stock performed over the past year?

Twist Bioscience Corp. returned +396.8% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Twist Bioscience Corp. do?

Twist Bioscience Corporation is a synthetic biology company that develops and sells DNA-based products for research and commercial applications. Twist Bioscience Corporation’s portfolio includes synthetic genes, gene fragments, oligonucleotide pools, and antibody libraries used in therapeutic discovery, diagnostics, agriculture, industrial biotechnology, and academic research.

What is the latest news on TWST?

The most recent item we track (ETF Trends, 9 Sept 2026): "AI & Robotics in 2026: 16 Recent Developments for Investors". An ETF Trends piece reports that August saw accelerating advances in AI and robotics, citing longer-running agents, faster and cheaper inference, AI systems engaging with laboratories and physical equipment, robots learning from fewer demonstrations, and new capital and infrastructure forming around commercial deployment.

Company

About Twist Bioscience Corp.

Twist Bioscience Corporation is a synthetic biology company that develops and sells DNA-based products for research and commercial applications. Twist Bioscience Corporation’s portfolio includes synthetic genes, gene fragments, oligonucleotide pools, and antibody libraries used in therapeutic discovery, diagnostics, agriculture, industrial biotechnology, and academic research. The company also supports advanced workflows such as targeted next-generation sequencing, CRISPR gene editing, mutagenesis, and DNA data storage. Its proprietary semiconductor-based DNA synthesis platform is designed to produce high-quality synthetic DNA at scale, helping customers move from design to experimentation more efficiently. Twist Bioscience Corporation serves biotechnology, pharmaceutical, industrial, and academic customers across multiple regions, making it an important supplier in the life sciences tools and synthetic biology market.

CEO Dr. Emily Marine Leproust Ph.D. · 979 employees · United States · https://www.twistbioscience.com